Navigation Links
Better Ways Needed to Track Drug Safety: Report
Date:5/1/2012

TUESDAY, May 1 (HealthDay News) -- A management plan to gather, assess and respond to data about all medications' risks from the time they are approved until they are no longer on the market is needed to improve drug safety in the United States, says an Institute of Medicine report released Tuesday.

The U.S. Food and Drug Administration approves new drugs based on clinical trial evidence that their benefits outweigh their risks. However, the full range of a medication's effects may not become apparent until it is used by a larger, more diverse population over a long period of time, the FDA-sponsored report noted.

A number of drugs approved by the FDA were later found to have problems, including the pain reliever Vioxx, the diabetes drug Avandia and the cholesterol-lowering drug Crestor.

Report recommendations include:

  • The risk- and benefit-assessment and management plan for each drug should be a publicly available document that would gather data about the drug during its entire time on the market.
  • The document should describe known safety concerns at the time of the drug's approval or that become evident as it is used by consumers.
  • The document should also include all FDA regulatory actions taken on a drug, such as restrictions on its use or ordering a manufacturer to conduct further research after approval (postmarket research).

"It is not possible to know what the full range of a drug's benefits and risks will be until it is used by many different kinds of patients over time, so it is critical that FDA continues to monitor and learn about the effects of drugs after they are marketed," said report committee co-chair Ruth Faden, a professor of biomedical ethics and executive director of the Berman Institute of Bioethics, Johns Hopkins University, said in an Institute of Medicine news release.

The FDA already gathers much of this information but it is scattered across multiple records. Collecting this information in a single, publicly accessible format would show the FDA's commitment to this drug "life-cycle" approach and make the process more open, according to the report.

Among its other recommendations, the report also said the FDA should order postmarket studies only if: a regulatory decision cannot be made based on existing safety evidence; the research can sufficiently address concerns about a drug's benefit-risk balance to help lead to a regulatory decision; the results will be used to make a regulatory decision in a timely fashion; and the rights and interests of the research participants can be adequately protected.

In addition, the FDA should ensure that postmarket studies it orders are conducted in ways that are ethically and scientifically sound, the report said.

"Our report focuses on how the agency can be proactive so that situations in which a drug's benefit-risk profile becomes problematic can be detected earlier, and it details how FDA can get the additional information on a drug's safety in the most ethical and scientifically sound ways when questions arise," Faden noted in the news release.

Report committee co-chair Steven Goodman, associate dean for clinical and translational research at Stanford University School of Medicine, added: "We believe that the adoption of a life-cycle approach to drug approval and monitoring will help the agency strengthen its oversight, better tackle these complex decisions, and increase public confidence in the agency's ability to protect public health. This will become increasingly important as FDA looks for ways to safely expedite the drug-approval process."

More information

The U.S. Food and Drug Administration outlines how it manages drug safety issues.

-- Robert Preidt

SOURCE: Institute of Medicine, news release, April 30, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Autism-Related Hypersensitivity Better Understood
2. Developing guidelines for better reporting of health research
3. Hawaiian-shirt.net Offers 10 Tips To Beat The Winter Blues: Things You Can Do Right Now to Have a Better Day
4. Better care at any hour for palliative patients
5. Patients Do Better at Hospitals That Follow Stroke Guidelines
6. More Expensive Hospital Care May Not Mean Better
7. New MRI May Lead to Better Brain Pictures
8. Biological clock could be a key to better health, longer life
9. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
10. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
11. New approach to immune cell analysis seen as first step to better distinguish health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Better Ways Needed to Track Drug Safety: Report
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
Breaking Medicine Technology: